MT-125

Jupiter, Florida-based Myosin Therapeutics has been awarded a USD 2 million grant from the Casey DeSantis Florida Cancer Innovation Fund to support its Phase I/II clinical trial evaluating MT-125 in patients with newly diagnosed glioblastoma. The Myosin Therapeutics STAR-GBM trial represents the first clinical evaluation of the company’s lead oncology candidate, a small molecule targeting molecular nanomotor proteins in tumor cells. The award, issued through the Florida Department of Health, will fund clinical trial activities at the Mayo Clinic campus in Jacksonville. What the Florida Cancer Innovation Fund grant supports The Casey DeSantis cancer fund operates as a statewide initiative under the Florida Department of Health, directing capital toward cancer therapy development and early-stage biotechnology companies operating within the state. Myosin Therapeutics was selected based on what the fund characterized as the scientific innovation and clinical potential of MT-125. The USD 2 million Florida Cancer Innovation Fund grant is earmarked specifically for the STAR-GBM trial rather than general corporate operations, tying the funding directly to clinical execution. The fund’s stated objectives include strengthening Florida’s life sciences ecosystem and accelerating the translation of laboratory research into patient-facing therapies. MT-125 inhibits non-muscle myosin II, impairing cytoskeletal contractility required for tumor cell invasion and proliferation. The resulting mitochondrial dysfunction and oxidative stress drive dependency on PDGFR signaling, supporting combination strategies with targeted kinase inhibitors. From a regulatory standpoint, MT-125 has received Orphan Drug Designation from the FDA for malignant gliomas and Fast Track Designation for glioblastoma. The STAR-GBM trial is structured as a Phase I/II study. The Phase I portion will assess safety, tolerability, and pharmacokinetics of MT-125 in newly diagnosed glioblastoma patients, generating data intended to inform dose selection for the Phase II expansion cohort. The trial is being conducted in collaboration with Mayo Clinic, and all three of Mayo Clinic’s US clinical research units are participating in the study, though the Florida campus serves as a primary site supported by this particular grant. Glioblastoma remains among the most treatment-resistant solid tumors, with a median overall survival of approximately 15 months under the current standard of care. New therapeutic approaches in this space have faced a high failure rate in clinical development, making any first-in-human study in GBM a consequential data-generating event for both the sponsor and the broader neuro-oncology field. Beyond glioblastoma, Myosin Therapeutics MT-125 is being developed for acute myeloid leukemia and pancreatic cancer, though the STAR-GBM trial is the first clinical program to enter human testing. The glioblastoma treatment Phase I/II study will therefore generate the initial human safety and pharmacokinetic dataset for the compound, with implications for the broader MT-125 development program across multiple tumor types. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

JUPITER, Fla., March 24, 2026 /PRNewswire/ -- Myosin Therapeutics today announced that it has been awarded $2 million in funding from the Florida Department of Health through the Casey DeSantis Florida Cancer Innovation Fund (FCIF) to support the company's STAR-GBM Phase 1/2 clinical trial evaluating MT-125 in patients newly diagnosed with glioblastoma (GBM). FCIF is a statewide initiative designed to accelerate the development of innovative cancer therapies and strengthen the life sciences ecosystem in Florida by supporting promising research programs and emerging biotechnology companies. Myosin Therapeutics was selected for funding based on the scientific innovation and clinical potential of MT-125, the company's lead oncology therapeutic candidate. The award will specifically support clinical trial activities being conducted at the Mayo Clinic campus in Jacksonville, FL. The Phase 1/2 STAR-GBM clinical trial represents the first clinical evaluation of MT-125 and is being conducted in collaboration with Mayo Clinic, with all three Mayo Clinic clinical research units in the U.S. participating in the study. The Phase 1 portion of the trial will evaluate safety, tolerability, and pharmacokinetics, while generating early clinical data to inform the Phase 2 dose expansion portion of the study. "We are honored to receive support from the Casey DeSantis Florida Cancer Innovation Fund as we bring MT-125 to patients," said Dr. Courtney Miller, Co-Founder and CEO of Myosin Therapeutics. "This funding helps support the continued progress of our Phase 1/2 STAR-GBM trial and reflects the growing strength of Florida's life sciences community in advancing innovative cancer therapies." Mayo Clinic's Florida campus is a leading academic medical center in the region and plays an important role in advancing new therapies through early-stage clinical trials. Participation of the Florida site in the STAR-GBM trial brings together specialized neuro-oncology expertise and clinical trial infrastructure to evaluate MT-125 in patients with newly diagnosed GBM. "This support from the Florida Department of Health will help accelerate the clinical development of MT-125 and strengthen Florida's role as a growing hub for biotechnology innovation," said Dr. Patrick Griffin, Co-founder and Chief Scientific Officer of Myosin Therapeutics. "Programs like FCIF play an important role in enabling emerging biotechs to translate promising scientific discoveries into clinical programs that can ultimately benefit patients." MT-125 is being developed for several treatment-resistant cancers, including acute myeloid leukemia and pancreatic cancer. And it has received Orphan Drug Designation for malignant gliomas and Fast Track Designation for glioblastoma, supporting an accelerated regulatory pathway for therapies addressing serious diseases with significant unmet medical need. About Myosin Therapeutics Myosin Therapeutics is a biotechnology company based in Jupiter, Florida, developing first-in-class therapies for oncology and CNS disorders by targeting molecular nanomotor proteins. The company's lead program, MT-125, is being developed for the treatment of multiple aggressive cancers by targeting the physical mechanics of tumor cells to prevent their growth and invasion into healthy tissues. Contact : [email protected] SOURCE Myosin Therapeutics Inc. 21% more press release views with Request a Demo